Clinical trial
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to…
NCT00122629 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Terminated
Key facts
| NCT number | NCT00122629 |
|---|---|
| Title | Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders |
| Official title | Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Schering-Plough Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | peg-interferon alfa-2b, ribavirin, amantadine |
| Enrollment | 405 |
| Start date | Oct 1, 2000 |
| Completion | May 1, 2003 |
| First posted | Jul 22, 2005 |
| Last update posted | Jul 29, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: